Literature DB >> 18466896

Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure.

Tanja Vihavainen1, Marjo Piltonen, Raimo K Tuominen, Esa R Korpi, Liisa Ahtee.   

Abstract

Previously we found that morphine's effects on locomotor activity and brain dopamine metabolism were enhanced in mice after cessation of 7-week oral nicotine treatment. In the present experiments we show that such chronic nicotine exposure cross-sensitizes NMRI mice to the reinforcing effect of morphine in the conditioned place preference paradigm. The nicotine-treated mice developed conditioned place preference after being conditioned twice with morphine 5 mg/kg s.c. whereas in control mice a higher dose (10 mg/kg) of morphine was required. Since the reinforcing effect of morphine is mediated via micro-opioid receptors we used [3H]DAMGO autoradiography to study whether the number (B(max)) or affinity (K(D)) of mu-opioid receptors in the mouse brain are affected following chronic nicotine exposure. However, no changes were found in the number or affinity of micro-opioid receptors in any of the brain areas studied. Neither did we find alterations in the functional activity of mu-opioid receptors studied by [35S]GTPgammaS-binding. In conclusion, chronic oral nicotine treatment augments the reinforcing effects of morphine in mice, and this cross-sensitization does not seem to be mediated by micro-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466896     DOI: 10.1016/j.ejphar.2008.03.028

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco.

Authors:  William S John; He Zhu; Paolo Mannelli; Geetha A Subramaniam; Robert P Schwartz; Jennifer McNeely; Li-Tzy Wu
Journal:  Drug Alcohol Depend       Date:  2018-11-26       Impact factor: 4.492

Review 2.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

3.  Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

4.  Tobacco Smoking, Nicotine Dependence, and Patterns of Prescription Opioid Misuse: Results From a Nationally Representative Sample.

Authors:  Emily L Zale; Michelle L Dorfman; W Michael Hooten; David O Warner; Michael J Zvolensky; Joseph W Ditre
Journal:  Nicotine Tob Res       Date:  2014-10-25       Impact factor: 4.244

5.  Tobacco Smoking and Brain Endogenous Opioid Release: More Than Nicotine Alone.

Authors:  Edward F Domino; Mika Hirasawa-Fujita
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

Review 6.  Anxiety and Depression in Bidirectional Relations Between Pain and Smoking: Implications for Smoking Cessation.

Authors:  Emily L Zale; Stephen A Maisto; Joseph W Ditre
Journal:  Behav Modif       Date:  2015-10-14

Review 7.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

8.  Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain.

Authors:  Martin D Cheatle; Mary Falcone; Lara Dhingra; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2020-02-14       Impact factor: 4.492

Review 9.  Nicotine: alcohol reward interactions.

Authors:  A Lajtha; H Sershen
Journal:  Neurochem Res       Date:  2010-05-25       Impact factor: 3.996

Review 10.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.